- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03648346
A Dose-escalation Clinical Trial After Multiple Dosing of HL217 Eye Drop in Healthy Male Subjects
A Dose Block-randomized, Double Blind, Placebo Controlled, Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Dosing of HL217 Eye Drop in Healthy Male Subjects
The study is a single center, double-blind, randomized, parallel group, multiple ascending dose study in 16 healthy male volunteers. Subjects will receive multiple eye drop doses during 14 days of the treatment (HL217 or placebo according to the randomization). There will be 2 cohorts of 8 subjects (6 HL217 vs 2 placebo) receiving the following doses:
- Cohort 1 : two drops of 3 mg/mL of the treatment in one eye twice a day (low dose),
- Cohort 2 : two drops of 3 mg/mL of the treatment in one eye 4 times a day (high dose).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Gières, France
- Eurofins Optimed
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male subject, aged between 18 and 50 years inclusive
- Non-smoker subject or smoker of not more than 10 cigarettes a day and able to stop smoking 24 hour prior to admission until discharge
- Body weight ≥ 50 kg and BMI between 18 and 30 kg/m²
- Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination) including complete ocular examination
Normal Blood Pressure (BP) and Heart Rate (HR) after 10 minutes in supine position:
- 90 mmHg ≤ Systolic Blood Pressure (SBP) ≤ 140 mmHg,
- 45 mmHg ≤ Diastolic Blood Pressure (DBP) ≤ 90 mmHg,
- 40 bpm ≤ HR ≤ 100 bpm,
- Or considered NCs by investigators;
Normal ECG recording on a 12-lead ECG:
- 120 < PR < 200 ms,
- QRS < 120 ms,
- QTcf ≤ 430 ms,
- No sign of any trouble of sinusal automatism,
- Or considered NCs by investigators;
- Laboratory parameters within the normal range of the laboratory (haematological, blood chemistry tests, urinalysis). Individual values out of the normal range can be accepted if judged clinically non relevant by the Investigator
- Normal dietary habits
- Signing a written informed consent prior to selection
- Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research.
Exclusion Criteria:
- Any history or presence of cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, haematological, neurologic, psychiatric, systemic, infectious or ocular disease
- Frequent headaches and / or migraine, recurrent nausea and / or vomiting
- Symptomatic hypotension whatever the decrease of blood pressure or asymptomatic postural hypotension defined by a decrease in SBP or DBP equal to or greater than 20 mmHg within two minutes when changing from the supine to the standing position
- Blood donation (including in the frame of a clinical trial) within 2 months before administration or apheresis within 20 days before administration
- General anaesthesia within 3 months before administration
- Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician (including allergy to fluorescein)
- Inability to abstain from intensive muscular effort;
- No possibility of contact in case of emergency;
- Any drug or herbal medicine intake (except paracetamol) during the last 14 days prior to the first administration, any over the counter medicine or vitamin during the last 7 days prior to the first administration
- Subjects who have taken drug metabolizing enzyme inducing agents and inhibitors such as barbitals within a month prior to the first administration
- History or presence of drug or alcohol abuse (alcohol consumption > 30 grams / day);
- Excessive consumption of beverages with xanthine bases (> 5 cups or glasses / day) and not able to stop 24h prior to admission until discharge
- Positive Hepatitis B surface (HBs) antigen or anti Hepatitis C Virus (HCV) antibody, or positive results for Human Immunodeficiency Virus (HIV) 1 or 2
- Major surgery (general or ocular) within 28 days prior to randomization or major surgery planned during the next 6 months
- Subject who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development
- Subjects within an exclusion period of a previous study or subjects who have taken any investigational product from other clinical trials within 60 days from the start of the study (from the administration of investigational product)
- Subjects with an allergy to Fluorescein
- Subjects with previous participation in the current study
- Subject under administrative or legal supervision
- Subject who would receive more than 4500 euros as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cohort 1: HL217 Ophathalmic Solution BID
Low dose: two drops of 3 mg/mL of the treatment in one eye twice a day
|
Two drops of 3 mg/mL of the treatment in one eye twice a day
Other Names:
|
EXPERIMENTAL: Cohort 2: HL217 Ophathalmic Solution QID
High dose: two drops of 3 mg/mL of the treatment in one eye 4 times a day
|
Two drops of 3 mg/mL of the treatment in one eye 4 times a day
Other Names:
|
PLACEBO_COMPARATOR: Placebo Ophathalmic Solution
Placebo: two drops of placebo in one eye twice a day or 4 times a day
|
Placebo eye drops
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical parameter: Adverse Events (AE)
Time Frame: Day 1 (Pre-dose) to Day 22 (End of study visit)
|
AEs will be coded according to the MedDRA.
They will be classified into pre-defined standard categories according to chronological criteria
|
Day 1 (Pre-dose) to Day 22 (End of study visit)
|
Clinical parameter: Physical examination
Time Frame: Day -1, Day 1 (Before administration, 4h, 8h, 12h), Day 2 (24h), Day 3 to 15, Day 22 (End of study visit)
|
Physical examination recorded during the study will be individually listed and quantitative parameters will be summarized by using descriptive statistics
|
Day -1, Day 1 (Before administration, 4h, 8h, 12h), Day 2 (24h), Day 3 to 15, Day 22 (End of study visit)
|
Clinical parameter: Vital signs
Time Frame: Day -1, Day 1 (Before administration, 4h, 8h, 12h), Day 2 (24h), Day 3 to 15, Day 22 (End of study visit)
|
Vital signs recorded during the study will be individually listed and quantitative parameters will be summarized by using descriptive statistics
|
Day -1, Day 1 (Before administration, 4h, 8h, 12h), Day 2 (24h), Day 3 to 15, Day 22 (End of study visit)
|
Clinical parameter: ECG (ElectroCardioGram)
Time Frame: Day -1, Day 1 (Before administration), Day 2, Day 15, Day 22 (End of study visit)
|
ECG recorded during the study will be individually listed and quantitative parameters will be summarized by using descriptive statistics
|
Day -1, Day 1 (Before administration), Day 2, Day 15, Day 22 (End of study visit)
|
Clinical parameter: Laboratory parameters
Time Frame: Day -1, Day 2, Day 15, Day 22 (End of study visit)
|
All laboratory values recorded during the study will be individually listed and flagged for values outside reference ranges and for clinical relevance (assessed by investigator)
|
Day -1, Day 2, Day 15, Day 22 (End of study visit)
|
Local tolerance test
Time Frame: Day -1, Day 1 (Before administration, 4h, 8h, 12h), Day 2 (24h), Day 3 to 15, Day 22 (End of study visit)
|
Redness, tingling and others should be checked
|
Day -1, Day 1 (Before administration, 4h, 8h, 12h), Day 2 (24h), Day 3 to 15, Day 22 (End of study visit)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic assessments: Cmax
Time Frame: 0h, 12h, 12h05min, 12h15min, 12h30min, 12h45min, 13h, 14h, 15h, 16h, 18h, 20h, 24h, 28h and 32hours after the last administration at Day 14
|
observed maximum plasma concentration of HL217
|
0h, 12h, 12h05min, 12h15min, 12h30min, 12h45min, 13h, 14h, 15h, 16h, 18h, 20h, 24h, 28h and 32hours after the last administration at Day 14
|
Pharmacokinetic assessments: Tmax
Time Frame: 0h, 12h, 12h05min, 12h15min, 12h30min, 12h45min, 13h, 14h, 15h, 16h, 18h, 20h, 24h, 28h and 32hours after the last administration at Day 14
|
first time to reach Cmax
|
0h, 12h, 12h05min, 12h15min, 12h30min, 12h45min, 13h, 14h, 15h, 16h, 18h, 20h, 24h, 28h and 32hours after the last administration at Day 14
|
Pharmacokinetic assessments: AUCt
Time Frame: 0h, 12h, 12h05min, 12h15min, 12h30min, 12h45min, 13h, 14h, 15h, 16h, 18h, 20h, 24h, 28h and 32hours after the last administration at Day 14
|
area under the plasma concentration curve from administration up to the last quantifiable concentration at time t
|
0h, 12h, 12h05min, 12h15min, 12h30min, 12h45min, 13h, 14h, 15h, 16h, 18h, 20h, 24h, 28h and 32hours after the last administration at Day 14
|
Pharmacokinetic assessments: AUCinf
Time Frame: 0h, 12h, 12h05min, 12h15min, 12h30min, 12h45min, 13h, 14h, 15h, 16h, 18h, 20h, 24h, 28h and 32hours after the last administration at Day 14
|
area under the plasma concentration-time curve from administration up to infinity with extrapolation of the terminal phase
|
0h, 12h, 12h05min, 12h15min, 12h30min, 12h45min, 13h, 14h, 15h, 16h, 18h, 20h, 24h, 28h and 32hours after the last administration at Day 14
|
Pharmacokinetic assessments: Kel
Time Frame: 0h, 12h, 12h05min, 12h15min, 12h30min, 12h45min, 13h, 14h, 15h, 16h, 18h, 20h, 24h, 28h and 32hours after the last administration at Day 14
|
elimination rate constant
|
0h, 12h, 12h05min, 12h15min, 12h30min, 12h45min, 13h, 14h, 15h, 16h, 18h, 20h, 24h, 28h and 32hours after the last administration at Day 14
|
Pharmacokinetic assessments: t1/2
Time Frame: 0h, 12h, 12h05min, 12h15min, 12h30min, 12h45min, 13h, 14h, 15h, 16h, 18h, 20h, 24h, 28h and 32hours after the last administration at Day 14
|
plasma elimination half-life
|
0h, 12h, 12h05min, 12h15min, 12h30min, 12h45min, 13h, 14h, 15h, 16h, 18h, 20h, 24h, 28h and 32hours after the last administration at Day 14
|
Pharmacokinetic assessments: %AUCextra
Time Frame: 0h, 12h, 12h05min, 12h15min, 12h30min, 12h45min, 13h, 14h, 15h, 16h, 18h, 20h, 24h, 28h and 32hours after the last administration at Day 14
|
percentage of extrapolated AUCinf
|
0h, 12h, 12h05min, 12h15min, 12h30min, 12h45min, 13h, 14h, 15h, 16h, 18h, 20h, 24h, 28h and 32hours after the last administration at Day 14
|
Pharmacokinetic assessments: Vd/F
Time Frame: 0h, 12h, 12h05min, 12h15min, 12h30min, 12h45min, 13h, 14h, 15h, 16h, 18h, 20h, 24h, 28h and 32hours after the last administration at Day 14
|
volume of distribution
|
0h, 12h, 12h05min, 12h15min, 12h30min, 12h45min, 13h, 14h, 15h, 16h, 18h, 20h, 24h, 28h and 32hours after the last administration at Day 14
|
Pharmacokinetic assessments: CL/F
Time Frame: 0h, 12h, 12h05min, 12h15min, 12h30min, 12h45min, 13h, 14h, 15h, 16h, 18h, 20h, 24h, 28h and 32hours after the last administration at Day 14
|
Clearance
|
0h, 12h, 12h05min, 12h15min, 12h30min, 12h45min, 13h, 14h, 15h, 16h, 18h, 20h, 24h, 28h and 32hours after the last administration at Day 14
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yves Donazzolo, M.D, Eurofins Optimed
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HL217-102
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Healthy Subjects | ImmunosuppressionUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
NeuShen TherapeuticsNot yet recruiting
-
GEN İlaç ve Sağlık Ürünleri A.Ş.Sulfateq B.V.Recruiting
-
Bio-innova Co., LtdNot yet recruiting
-
Bio-innova Co., LtdNot yet recruiting
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States